Manure & crops
Resistant bacteria canreach soil and produce.
41 combinations screened · 7 leads selected
Farm antibiotics are failing. We are building practical replacements.
Green Antibiotics designs defined, plant-derived antimicrobial combinations for poultry and aquaculture. Reproducible in-vitro activity against MRSA and multidrug-resistant Salmonella Typhi supports an early regional route while the wider regulatory dossier is built. Both are WHO high-priority pathogens4.
01 ·The problem
Resistance selected in animal production can become a human-health problem.
WHO identifies food, direct animal contact and environmental pathways through which resistant bacteria can move from food-producing animals to people. The importance of each route varies, but the One Health connection is clear4.
- Protect essential medicines. WHO calls for prudent antimicrobial use across human health, animal health and food production.20
- Treat AMR as one connected system. Resistant organisms and residues can move among animals, people, food, water and soil.20
- Measure across sectors. The 2025 Quadripartite guidance links surveillance in human, animal, plant and environmental settings.21
- Build practical alternatives. A feed solution must be standardised, stable, safe, affordable and supported by controlled animal evidence.
Antibiotic use in animal agricultureResistance can emerge across food-producing animals
Poultry
Cattle
Goats
Sheep
Pigs
Fish
Animal waste
Waste and run-off cancarry resistant bacteria.
Food chain
Contaminated food cancarry resistant bacteria.
Direct contact
Workers and families maybe directly exposed.
One Health consequenceResistant bacteria can spread to people
39m
Lives at risk
Deaths directly attributable to bacterial AMR forecast between 2025 and 20501.
US$1.7tn
GDP at risk
Potential annual global GDP loss by 2050, with US$28 returned per US$1 invested in action6.
11.8m
South Asia
Attributable deaths projected for South Asia alone, the highest regional burden1.
02 ·Our approach
A discovery platform, not a herbal blend.
Single plant extracts have been fed to animals for decades with inconsistent results. Avix instead applies literature-guided compound selection, AI and machine-learning-assisted analysis, and defined multi-compound cocktails screened systematically against priority pathogens. The platform is designed to produce candidates matched to a species, pathogen and production system.
- 41 defined combinations screened against resistant isolates.
- 7 lead cocktails advanced; 34 were stopped and recorded.
- Every lead combines three complementary compounds.
- Co-developed with Dr David Brown, originator of the antibiotic-resistance-breaker concept5.
Measured zones of inhibition — AV-01 series
Disc diffusion on clinical isolates, repeated assays. Larger zones indicate greater activity within the same assay. Zone diameters do not establish dose-normalised potency against a structurally different comparator; see Evidence for interpretation and limits.
03 ·The programme
Two drug discoverers. One focused screening programme.
Green Antibiotics was designed and run jointly by Dr Md Arif Sheikh, a molecular and structural biologist with more than nineteen years in drug discovery, and Dr David Brown, the drug discoverer who introduced the antibiotic resistance breaker concept in Nature Reviews Drug Discovery5.
Avix has already carried a product from laboratory concept through formulation, a completed human clinical study and manufacturing coordination. That operational track record is what turns a screening result into a programme.
04 ·Where we are
Exactly where the programme stands today.
The programme is early, defined and ready for the next evidence-building stage.
- Reproducible in-vitro proof of concept.
- Seven leads selected from 41 screened combinations.
- A costed twelve-month validation and development plan.
- No filed IP, animal data or authorised product yet.
Current position
Clear evidence boundaries and a defined next gate
- Seven reproducible in-vitro leads selected from 41 screened combinations.
- Patent filing, MIC/MBC, safety and controlled poultry evidence remain outstanding.
- The funded twelve-month plan connects IP, validation and a lawful regional commercial route.
- The updated global AMR plan prioritises One Health surveillance, prevention and research innovation.22
Scientific references8 sources used on this page
World Health Organization.
World Health Organization. WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development and public health strategies against antimicrobial resistance. The Lancet Infectious Diseases, 2025. doi:10.1016/S1473-3099(25)00118-5
GBD 2021 Antimicrobial Resistance Collaborators.
GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, 404(10459):1199–1226, 2024. doi:10.1016/S0140-6736(24)01867-1
Acosta A, Tirado M V, Cheng L, et al.
Acosta A, Tirado M V, Cheng L, et al. The future of antibiotic use in livestock. Nature Communications, 16, 2025. doi:10.1038/s41467-025-56825-7
World Health Organization.
World Health Organization. Antimicrobial resistance: leading a global One Health response, including inappropriate antimicrobial use in human health, animal health, food production and environmental pathways. who.int
WHO, FAO, UNEP and WOAH.
WHO, FAO, UNEP and WOAH. Quadripartite guidance on One Health integrated surveillance of antimicrobial resistance and use, 2025. openknowledge.fao.org
World Organisation for Animal Health (WOAH) and partners.
World Organisation for Animal Health (WOAH) and partners. EcoAMR series: Health and Economic Impacts of Antimicrobial Resistance in Humans and Food-Producing Animals, 2024. woah.org
Brown D.
Brown D. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nature Reviews Drug Discovery, 14:821–832, 2015. doi:10.1038/nrd4675 — authored by Green Antibiotics co-developer Dr David Brown.
World Organisation for Animal Health.
World Organisation for Animal Health. Updated Global Action Plan on Antimicrobial Resistance 2026–2036: One Health surveillance, prevention, appropriate use, research, governance and accountability. woah.org